EE05270B1 - Mittekristallilise kaltsiumatorvastatiini valmistamismeetod - Google Patents

Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Info

Publication number
EE05270B1
EE05270B1 EEP200300333A EEP200300333A EE05270B1 EE 05270 B1 EE05270 B1 EE 05270B1 EE P200300333 A EEP200300333 A EE P200300333A EE P200300333 A EEP200300333 A EE P200300333A EE 05270 B1 EE05270 B1 EE 05270B1
Authority
EE
Estonia
Prior art keywords
atorvastatin
crystalline
calcium
oratorvastatin
preparation
Prior art date
Application number
EEP200300333A
Other languages
English (en)
Estonian (et)
Inventor
Sorsak Gorazd
Original Assignee
Lek Pharmaceutical And Chemical Company D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceutical And Chemical Company D.D. filed Critical Lek Pharmaceutical And Chemical Company D.D.
Publication of EE200300333A publication Critical patent/EE200300333A/xx
Publication of EE05270B1 publication Critical patent/EE05270B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200300333A 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod EE05270B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200100010A SI20814A (sl) 2001-01-23 2001-01-23 Priprava amorfnega atorvastatina
PCT/IB2002/000161 WO2002059087A1 (fr) 2001-01-23 2002-01-22 Preparation de calcium d'atorvastatine non cristallin

Publications (2)

Publication Number Publication Date
EE200300333A EE200300333A (et) 2003-10-15
EE05270B1 true EE05270B1 (et) 2010-02-15

Family

ID=20432812

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300333A EE05270B1 (et) 2001-01-23 2002-01-22 Mittekristallilise kaltsiumatorvastatiini valmistamismeetod

Country Status (27)

Country Link
US (2) US6750353B2 (fr)
EP (1) EP1373202B1 (fr)
JP (1) JP4336106B2 (fr)
KR (1) KR100882066B1 (fr)
CN (1) CN1260213C (fr)
AT (1) ATE294159T1 (fr)
AU (1) AU2002219455B2 (fr)
BG (1) BG108017A (fr)
BR (1) BR0206637A (fr)
CA (1) CA2435954C (fr)
CZ (1) CZ20031988A3 (fr)
DE (1) DE60203894T2 (fr)
DK (1) DK1373202T3 (fr)
EE (1) EE05270B1 (fr)
ES (1) ES2240748T3 (fr)
HR (1) HRP20030575B1 (fr)
HU (1) HU227535B1 (fr)
IL (2) IL157068A0 (fr)
MX (1) MXPA03006548A (fr)
PL (1) PL209428B1 (fr)
RS (1) RS51010B (fr)
RU (1) RU2324679C2 (fr)
SI (2) SI20814A (fr)
SK (1) SK286593B6 (fr)
UA (1) UA73829C2 (fr)
WO (1) WO2002059087A1 (fr)
ZA (1) ZA200305307B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
CA2623599A1 (fr) 2000-12-27 2002-07-04 Paul Adrian Van Der Schaaf Formes cristallines d'atorvastatine
AU2002216359A1 (en) * 2001-02-27 2002-09-12 Council Of Scientific And Industrial Research Essential oil composition for potable water disinfection
CN1524073A (zh) 2001-06-29 2004-08-25 ����-�����ع�˾ ′R-(R*,R*)-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基氨基）羰基-1H-吡咯-1-庚酸钙盐（2∶1）（阿托伐他汀）
WO2005033078A1 (fr) * 2003-10-07 2005-04-14 Biocon Limited Procede de production d'atorvastatine calcique
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
KR20090045419A (ko) 2002-02-19 2009-05-07 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
CA2385529A1 (fr) * 2002-05-21 2003-11-21 Bernard Charles Sherman Formulations posologiques stables contenant de l'atorvastatin calcium
BRPI0409292A (pt) 2003-04-11 2006-04-11 Lek Pharmaceuticals processo para a preparação de sal de cálcio amorfo de atorvastatina
US7790197B2 (en) 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP1648903A2 (fr) 2003-07-02 2006-04-26 Egis Gyogyszergyar Rt. Procede de fabrication d'une forme amorphe d'un medicament inhibant l'agregation plaquettaire
AU2003247327A1 (en) * 2003-07-15 2005-01-28 Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form
US7943786B2 (en) * 2003-12-29 2011-05-17 Ljubomir Antoncic Process for preparing amorphous (4R-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
FI120344B (fi) 2004-03-17 2009-09-30 Ranbaxy Lab Ltd Menetelmä amorfisessa muodossa olevan atorvastatiinikalsiumin valmistamiseksi
WO2005105738A2 (fr) 2004-05-05 2005-11-10 Pfizer Products Inc. Formes salines d'acide [r-(r*, r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique
BRPI0513396A (pt) * 2004-07-16 2008-05-06 Lek Pharmaceuticals produtos de degradação oxidativa de atorvastatina de cálcio
CA2754932C (fr) 2004-07-20 2014-04-01 Warner-Lambert Company Llc Nouvelles formes de [r-(r*,r*)]-2-(4-fluorophenyl).beta.,.delta.-dihydroxy-5-(isopropyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoatede calcium (2:1)
WO2006011155A1 (fr) * 2004-07-26 2006-02-02 Apollo International Limited Procede en enceinte unique pour calcium d'atorvastatine amorphe
CA2578722C (fr) * 2004-08-27 2010-02-02 Biocon Limited Processus pour calcium d'atorvastatine amorphe
MX2007004722A (es) 2004-10-28 2007-06-15 Warner Lambert Co Procedimiento para formar atorvastatina amorfa.
ES2270722B1 (es) * 2005-09-15 2008-03-01 Ercros Industrial, S.A. Procedimiento para la obtencion de atorvastatina calcica amorfa.
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (fr) * 2005-09-21 2007-03-21 Renuka D. Reddy Procede de recuit de l'atorvastatine amorphe
WO2007057755A1 (fr) 2005-11-21 2007-05-24 Warner-Lambert Company Llc Nouvelles formes d’acide [r-(r*,r*)]-2-(4-fluorophenyl)-b,b-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique magnesium
EP1810667A1 (fr) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique contenant de l'atorvastatin amorphé
US20090099371A1 (en) * 2006-01-31 2009-04-16 Runjhun Gupta Process for the preparation of amorphous atorvastatin calcium salt
CN100406438C (zh) * 2006-06-30 2008-07-30 浙江新东港药业股份有限公司 一种无定型阿伐他汀钙的制备方法
WO2008053312A2 (fr) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Procédé de préparation d'un sel d'hémicalcium d'atorvastatine amorphe et intermédiaire de ce dernier
KR100833439B1 (ko) * 2007-01-02 2008-05-29 씨제이제일제당 (주) 비결정형 아토르바스타틴 칼슘의 개선된 제조방법
CN101969766B (zh) * 2007-10-17 2015-05-06 托德·F·奥沃凯泰斯 固态化合物的改良方法及使用其制备的共-无定形组合物
WO2009139730A1 (fr) * 2008-05-13 2009-11-19 Ulkar Kimya San. Ve Tic. A.S. Fabrication de nouvelles formes non cristallines d'atorvastatine calcique
KR101050722B1 (ko) 2008-12-02 2011-07-21 대웅바이오 주식회사 무정형 아토르바스타틴 칼슘염의 제조방법
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US20130041162A1 (en) * 2010-04-19 2013-02-14 Dsm Sinochem Pharmaceuticals Netherlands B.V. Production of atorvastatin low in ether impurities
HUP1000299A2 (hu) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra
CN102796036B (zh) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 一种阿托伐他汀钙的制备方法
US10202598B2 (en) 2014-05-30 2019-02-12 Todd Frank Ovokaitys Methods and systems for generation, use, and delivery of activated stem cells
US10040728B2 (en) 2014-06-06 2018-08-07 Todd Frank Ovokaitys Methods and compositions for increasing the bioactivity of nutrients
US10384985B2 (en) 2014-06-06 2019-08-20 B.K. Consultants, Inc. Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants
CN113321607A (zh) * 2020-02-28 2021-08-31 北京福元医药股份有限公司沧州分公司 一种阿托伐他汀钙中间体的纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
DE69616808T2 (de) * 1995-07-17 2002-05-29 Warner Lambert Co Kristallines (r-(r*,r*))-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrol-1-heptancarbonsäure hemi calcium salz (atorvastatin)
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
HRP960312B1 (en) * 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
IN191236B (fr) * 1999-05-25 2003-10-11 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
DK1373202T3 (da) 2005-05-17
DE60203894D1 (de) 2005-06-02
BR0206637A (pt) 2004-08-03
EP1373202A1 (fr) 2004-01-02
JP4336106B2 (ja) 2009-09-30
KR100882066B1 (ko) 2009-02-10
BG108017A (bg) 2004-08-31
UA73829C2 (en) 2005-09-15
AU2002219455B2 (en) 2007-04-26
CA2435954A1 (fr) 2002-08-01
CA2435954C (fr) 2008-06-03
JP2005503997A (ja) 2005-02-10
SK9082003A3 (en) 2003-12-02
SK286593B6 (sk) 2009-01-07
HUP0302797A3 (en) 2009-09-28
PL361763A1 (en) 2004-10-04
ATE294159T1 (de) 2005-05-15
US20030109569A1 (en) 2003-06-12
RS51010B (sr) 2010-10-31
RU2324679C2 (ru) 2008-05-20
CN1487921A (zh) 2004-04-07
SI20814A (sl) 2002-08-31
WO2002059087A1 (fr) 2002-08-01
RU2003124962A (ru) 2005-01-10
IL157068A0 (en) 2004-02-08
CN1260213C (zh) 2006-06-21
HRP20030575B1 (en) 2011-10-31
MXPA03006548A (es) 2004-10-15
IL157068A (en) 2009-09-01
KR20030077003A (ko) 2003-09-29
YU56803A (sh) 2006-05-25
SI1373202T1 (sl) 2005-12-31
ES2240748T3 (es) 2005-10-16
US7074940B2 (en) 2006-07-11
DE60203894T2 (de) 2006-01-19
PL209428B1 (pl) 2011-08-31
EP1373202B1 (fr) 2005-04-27
HUP0302797A2 (hu) 2003-11-28
HU227535B1 (en) 2011-08-29
ZA200305307B (en) 2004-07-09
US20040072895A1 (en) 2004-04-15
EE200300333A (et) 2003-10-15
US6750353B2 (en) 2004-06-15
HRP20030575A2 (en) 2005-06-30
CZ20031988A3 (cs) 2003-11-12

Similar Documents

Publication Publication Date Title
EE200300333A (et) Mittekristallilise kaltsiumatorvastatiini valmistamismeetod
WO2001096334A3 (fr) Acides heteroarylalkanoiques utilises comme antagonistes des recepteurs d'integrine
AU5669398A (en) Novel cyclosporin derivatives, method of preparation and pharmaceutical compositions containing them
DK0891325T3 (da) Para-substituerede phenylpropansyrederivater som integrinantagonister
WO2004062601A3 (fr) Agents antibacteriens
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
WO2001096307A3 (fr) Acides alcanoiques cycloalkyles comme antagonistes d'integrines
WO2004096823A3 (fr) Nouveaux derives de ketolides
WO2001064645A3 (fr) Derives de quinoline utilises comme antagonistes alpha2
ES2307511T3 (es) Derivados de eritromicina c-2 modificados.
FI962418A (fi) Syklisiä amidijohdannaisia neurokiniini A antagonisteina
WO2001027110A3 (fr) Derives d'imidazo-3-yl-amine bicycliques substitues sur le sixieme chainon
NO973652D0 (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyre og derivater som tachykininreseptor-antagonist
TNSN05247A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
EP1329218A4 (fr) Agents preventifs/remedes destines a l'hypertension portale
CA2393757A1 (fr) Antagonistes du recepteur ccr5 de la cycloamine
WO2001081316A3 (fr) Inhibiteurs de phenyle farnesyltransferase substitues
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
EA200300272A1 (ru) Новые производные хиназолина, способ их получения и фармацевтические композиции, содержащие их
MXPA02011402A (es) Un polimorfo v novedoso de torasemida.
MX9207204A (es) Preparado farmaceutico y procedimiento para su fabricacion.
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques

Legal Events

Date Code Title Description
HB1A Correction of owner name or address
HC1A Change of owner name
HC1A Change of owner name
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20130122